Reference : Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/2268/83954
Can NF-kappaB be a target for novel and efficient anti-cancer agents?
English
Olivier, Sabine mailto [Université de Liège - ULg > Département de sciences fonctionnelles > Biochimie et biologie moléculaire >]
Robe, Pierre mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Génétique générale et humaine - Département des sciences biomédicales et précliniques >]
Bours, Vincent mailto [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >]
2006
Biochemical Pharmacology
Elsevier Science
72
9
1054-1068
Yes
International
0006-2952
Oxford
United Kingdom
[en] Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use ; Antineoplastic Agents/pharmacology/therapeutic use ; Boronic Acids/pharmacology/therapeutic use ; Glucocorticoids/pharmacology/therapeutic use ; Humans ; I-kappa B Kinase/antagonists & inhibitors ; Multiple Myeloma/drug therapy ; NF-kappa B/antagonists & inhibitors/metabolism ; Phosphorylation ; Proteasome Endopeptidase Complex/antagonists & inhibitors ; Pyrazines/pharmacology/therapeutic use
[en] Since the discovery of the NF-kappaB transcription factor in 1986 and the cloning of the genes coding for NF-kappaB and IkappaB proteins, many studies demonstrated that this transcription factor can, in most cases, protect transformed cells from apoptosis and therefore participate in the onset or progression of many human cancers. Molecular studies demonstrated that ancient widely used drugs, known for their chemopreventive or therapeutic activities against human cancers, inhibit NF-kappaB, usually among other biological effects. It is therefore considered that the anti-cancer activities of NSAIDs (non-steroidal anti-inflammatory drugs) or glucocorticoids are probably partially related to the inhibition of NF-kappaB and new clinical trials are being initiated with old compounds such as sulfasalazine. In parallel, many companies have developed novel agents acting on the NF-kappaB pathway: some of these agents are supposed to be NF-kappaB specific (i.e. IKK inhibitors) while others have wide-range biological activities (i.e. proteasome inhibitors). Today, the most significant clinical data have been obtained with bortezomib, a proteasome inhibitor, for the treatment of multiple myeloma. This review discusses the preclinical and clinical data obtained with these various drugs and their putative future developments.
http://hdl.handle.net/2268/83954
also: http://hdl.handle.net/2268/67810
10.1016/j.bcp.2006.07.023

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
reviewnfkb.pdfPublisher postprint260.76 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.